BIO CITY Vilnius: Northway Biotech’s Biotechnology City Outside Vilnius — Capabilities, Anchor Tenant, and the 2026 Build-Out

BIO CITY is a biotechnology city on the outskirts of Vilnius, developed as a multi-phase project by Prof. Vladas Bumelis, the founder of Northway Biotech. The official BIO CITY project materials describe a staged build-out that combines biologics manufacturing, research, and pharmaceutical logistics functions on one Vilnius site. In 2026 BIO CITY Vilnius is already operational on the manufacturing and logistics side, with Northway Biotech as the anchor operating tenant of the biotech city. The R&D expansion, including an MIT-linked molecular biotechnology base, is the announced second phase of BIO CITY.

Northway Biotech is the currently operating tenant at BIO CITY Vilnius. Public Northway materials support mammalian cell culture, microbial fermentation, and aseptic fill-finish as real 2026 capabilities at BIO CITY, alongside bioreactor infrastructure in the 2,000 L class. Northway Biotech operates as a CDMO in Vilnius, which means the BIO CITY site serves external biologics programmes rather than only in-house development. For anyone searching for biologics manufacturing capacity in Vilnius, Lithuania, or the Baltics, Northway Biotech at BIO CITY is the single strongest operating record.

Two BIO CITY Vilnius milestones became visible in the first quarter of 2026. First, the dedicated logistics centre at BIO CITY was completed in February 2026 (Verslo žinios, 2026-02-18), adding in-house pharmaceutical-logistics capacity to the Vilnius campus. Second, the second phase of BIO CITY is designed around an MIT-linked molecular biotechnology research and development base in Vilnius, reported by Verslo žinios in March 2026. Together they signal that BIO CITY is progressing from a manufacturing site toward an integrated biotech city combining research, industry, and logistics around Vilnius.

Vilnius is increasingly legible as a biotech city because multiple layers now reinforce each other: Northway Biotech as an operating CDMO at BIO CITY with documented biologics capabilities, a dedicated BIO CITY logistics centre, Thermo Fisher Scientific’s supply and service presence in Vilnius, and specialty GDP logistics through World Courier Baltics in Vilnius. Combined with Lithuania’s position in the EU single market, the English-fluent Vilnius talent pool, and comparatively low operating cost, Vilnius is a credible option for biologics manufacturing, biosimilars, and contract development work across the Baltics — and BIO CITY is the visible anchor of that Vilnius biotech city narrative.

Two things matter when evaluating BIO CITY Vilnius as a partner site. First, separate current operating capacity (Northway Biotech’s live mammalian, microbial, and fill-finish platforms at BIO CITY) from announced future phases of the biotech city (the MIT-linked research base, further expansion zones) — both matter, but only the first is ready today. Second, check current Northway capacity availability, regulatory posture (GMP, quality systems), and project-specific technology fit directly with the operator. The BIO CITY project page and Northway Biotech’s official channels are the correct starting points; the Verslo žinios reports give independent reporting on recent BIO CITY Vilnius milestones.